Sclerostin is a risk factor for mortality after kidney transplantation
Researchers have identified the soluble WNT pathway inhibitor SCLEROSTIN as an independent risk factor for all-cause #mortality in patients after kidney transplantation.
600 stable renal transplant recipients were followed for all-cause mortality for 3 years.
Sclerostin is an independent risk factor for all-cause mortality in kidney transplant recipients.
Zeng S et al., Clin Exp Nephrology (2020). Click link for full text.
Biomedica Sclerostin ELISA: https://www.bmgrp.com/product/cardiovascular/sclerostin-elisa-human-sost-biomedica/
√ HIGH QUALITY – fully validated assay according to ICH/FDA/EMEA guidelines
√ LOW SAMPLE VOLUME – only 20 µl sample / well
√ EASY – convenient ready to use protocol
√ MOST REFERENCED Sclerostin ELISA
Also available: Bioactive Sclerostin ELISA https://www.bmgrp.com/product/cardiovascular/biomedica-bioactive-sclerostin-elisa-human-sost/
√ specific antibodies targeting the receptor binging region